Emergent Biosolutions Company Profile (NYSE:EBS)

Analyst Ratings

Consensus Ratings for Emergent Biosolutions (NYSE:EBS) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $42.33 (26.59% upside)

Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Singular ResearchLower Price TargetBuy$44.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015Summer StreetReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2015JPMorgan Chase & Co.Boost Price TargetOverweight$32.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Emergent Biosolutions (NYSE:EBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4$0.70$0.78$168.07 million$168.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q1($0.45)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q115$0.69$0.75$147.00 million$148.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q414$0.52$0.49$126.90 million$138.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.32$0.25$109.25 million$110.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.14)($0.55)$57.30 million$53.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012$0.21$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2012$0.72$0.78ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.04)$0.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011$0.33$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2011$0.67$0.76ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Emergent Biosolutions (NYSE:EBS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Emergent Biosolutions (NYSE:EBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.67View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Emergent Biosolutions (NYSE:EBS)
DateHeadline
07/25/16 01:29 PMTwo Under The Radar Biotech Decisions To Watch Next Month -
07/24/16 03:32 PMLong Term Emergent (EBS) Investors: Shareholder...
07/24/16 08:17 AMIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven, A Maryland-Based Securities Litigation Law Firm, Notifies Shareholders of Securities Class Action…
07/23/16 03:38 PMLong Term Emergent (EBS) Investors: Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigation …
07/23/16 12:04 PMEMERGENT BIOSOLUTIONS INC. Financials -
07/23/16 09:27 AMLong Term Emergent (EBS) Investors: Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigation of Emergent BioSolutions, Inc.; Encourages Long Term Investors to Contact the Firm - [PR Newswire] - SAN DIEGO, July 23, 2016 /PRNewswire-USNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal and state securities laws by Emergent BioSolutions, Inc. (EBS) and certain of its officers and board members. Emergent BioSolutions is a specialty biopharmaceutical company that develops, manufactures and sells specialized products to healthcare providers and governments. Specifically, a class action has been commenced in the USDC for the District of Maryland, on behalf of purchasers of Emergent Biosolutions securities between January 11, 2016 and June 21, 2016.
07/23/16 07:50 AMEMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS …
07/22/16 10:10 PMIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven, A Maryland-Based Securities Litigation Law Firm, Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Emer - [GlobeNewswire] - STEVENSON, Md., July 22, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...
07/22/16 09:41 PMEMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS - [GlobeNewswire] - NEW ORLEANS, July 22, 2016-- Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead ...
07/22/16 03:40 PMINVESTOR ALERT: Hagens Berman Alerts Emergent Biosolutions, Inc. (NYSE: EBS ...
07/22/16 11:00 AMIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. . Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive , are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.
07/22/16 08:30 AMINVESTOR ALERT: Hagens Berman Alerts Emergent Biosolutions, Inc. (NYSE: EBS) Investors to Securities Class Action and September 19, 2016 Lead Plaintiff Deadline - [GlobeNewswire] - SAN FRANCISCO, July 22, 2016-- Hagens Berman Sobol Shapiro LLP alerts investors of Emergent Biosolutions, Inc. that a securities class action is pending in the United States District Court for the District ...
07/21/16 09:14 PMHC Stocks Indications: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Emergent Biosolutions Inc (NYSE:EBS) - share market updates (press release)
07/21/16 09:14 PMIs $47 Price Target Attainable For Emergent Biosolutions, Inc. (NYSE:EBS)? - Investor Newswire
07/21/16 09:14 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent Biosolutions, Inc ... - PR Newswire (press release)
07/21/16 03:54 PMRosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS
07/21/16 03:54 PMEmergent BioSolutions (EBS) Says Aptevo (APVO) Will Begin Trading on 'When Issued' Basis Today
07/21/16 03:15 PMEmergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016 - [GlobeNewswire] - GAITHERSBURG, Md., July 21, 2016-- Emergent BioSolutions Inc. will host a conference call on Thursday, August 4, 2016 at 5:00 pm to discuss the financial results for the second quarter of 2016, provide ...
07/21/16 01:03 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent Biosolutions, Inc. - EBS - [PR Newswire] - NEW YORK, July 21, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent Biosolutions, Inc. ("Emergent" or the "Company") (EBS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. On this news, Emergent's stock price fell $7.99 per share, or more than 20%, to close at $31.33 on June 22, 2016.
07/21/16 04:45 AMIMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. And Reminds Investors with Losses to Contact The Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company") (NYSE: ...
07/20/16 07:30 PMGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. (EBS) - [GlobeNewswire] - NEW YORK, July 20, 2016-- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. in the United States District Court for the District of Maryland ...
07/20/16 05:39 PMINVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. . Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 are encouraged to contact the firm in advance of the September 19, 2016 lead plaintiff motion deadline.
07/20/16 04:56 PMEmergent BioSolutions (EBS) Says Aptevo (APVO) Will Begin Trading on 'When Issued' Basis Today - StreetInsider.com
07/20/16 04:30 PMBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. (EBS) and Encourages Investors to Contact the Firm - [Business Wire] - Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities who acquired Emergent BioSolutions, Inc.
07/20/16 04:00 PMIMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. . Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive , are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.
07/20/16 03:30 PMSafirstein Metcalf LLP Announces That a Class Action Lawsuit Has Been Filed Against Emergent Biosolutions Inc. - EBS - [GlobeNewswire] - NEW YORK, July 20, 2016-- Safirstein Metcalf LLP announces that a complaint has been filed on behalf of purchasers of Emergent Biosolutions Inc. common stock during the period between January 11, 2016 ...
07/20/16 03:25 PMINVESTOR ALERT: Investigation of Emergent BioSolutions, Inc. Announced by Law Offices of Howard G. Smith - [Business Wire] - Law Offices of Howard G. Smith announces an investigation on behalf of investors of Emergent BioSolutions, Inc. concerning the Company and its officers’ possible violations of federal securities laws.
07/20/16 02:11 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Emergent Biosolutions, Inc (EBS) & Lead Plaintiff Deadline: September 19, 2016 - [PR Newswire] - NEW YORK, July 20, 2016 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of Maryland on behalf of those who purchased shares of Emergent Biosolutions, Inc. ("Emergent" or the "Company") (EBS) during the period between January 11, 2016 and June 21, 2016, inclusive (the "Class Period"). Emergent is a multinational specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases, oncology and autoimmune disorders, and provides medical devices for biodefense purposes. Emergent's anthrax vaccine, BioThrax (Anthrax Vaccine Adsorbed) ("BioThrax"), is the only Anthrax vaccine licensed by the U.S. Food and Drug Administration ("FDA"). In September 2011, Emergent entered into a five-year procurement contract with the U.S. government for 44.75 million doses of BioThrax and by January 2016, Emergent reported it had sold out of its BioThrax and was expanding its BioThrax manufacturing facilities.
07/20/16 02:04 PMInvestor sues Emergent BioSolutions over demand for anthrax vaccine -
07/20/16 12:41 PMEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS - [Business Wire] - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Emergent BioSolutions, Inc. common stock from January 11, 2016 through June 21, 2016, both dates inclusive .
07/20/16 10:42 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 19, 2016 – EBS - [GlobeNewswire] - NEW YORK, July 20, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. between ...
07/20/16 07:23 AMEmergent Biosolutions Incorporated (NYSE:EBS) Shorted Shares Increased By 28.31% - Press Telegraph
07/19/16 09:50 AMShares Lower on the Year Emergent BioSolutions, Inc. (NYSE:EBS) - Press Telegraph
07/18/16 03:50 PMNYSE:EBS Stockholder Notice: Investigation over possible Securities Laws Violations by Emergent Biosolutions Inc
07/18/16 03:50 PMInvestor News: Emergent Biosolutions Inc (NYSE:EBS) under Investigation over possible Violations of Securities Laws
07/17/16 08:17 AMAnalysts: Emergent BioSolutions, Inc. (NYSE:EBS) stock is worth $42 - Review Fortune
07/16/16 07:09 AMEmergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement - P&T Community
07/15/16 12:49 PMEmergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement - [at noodls] - Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that ...
07/15/16 12:27 PMEmergent BioSolutions To Implement $50 Million Share Buyback Program -
07/15/16 10:55 AMInstitutions are Increasing Positions in Emergent BioSolutions, Inc. (NYSE:EBS) - Engelwood Daily
07/15/16 10:55 AMStrong Sell Calls For Emergent Biosolutions, Inc. (NYSE:EBS) At 0 - Investor Newswire
07/15/16 07:35 AMShould You Get Rid of Emergent BioSolutions (EBS) Now? -
07/15/16 06:18 AMEmergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock - [at noodls] - GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company's management to implement a stock repurchase ...
07/14/16 08:28 AM14.07.2016 - Erste Group expects to post net profit of approx. EUR 560 million in Q2 16, raises guidance for 2016 to ROTE>12% (up from 10-11%) - [at noodls] - 14.07.2016 - Erste Group expects to post net profit of approx. EUR 560 million in Q2 16, raises guidance for 2016 to ROTE>12% (up from 10-11%) The text version of this document is not available at the ...
07/13/16 09:01 PMAre Analysts Bullish Emergent Biosolutions Inc (NYSE:EBS) After Last Week? - Consumer Eagle
07/13/16 07:13 AMSabine Mlnarsky on her way to Erste Group - [at noodls] - Sabine Mlnarsky will assume the role of Head of Human Resources at Erste Group in Austria starting in October. In this function, she will be responsible for the two legal units 'Holding' and 'Erste Bank'. ...
07/12/16 03:55 PMEmergent BioSolutions (EBS) Board Approves Spin of Aptevo Therapeutics; Declares Dividend Distribution
07/12/16 08:01 AMStock Down on the Year Emergent BioSolutions, Inc. (NYSE:EBS) - Press Telegraph
07/12/16 02:43 AM11.07.2016 - Publication of a transaction regarding Erste Group shares in compliance with section 7 Publication Ordinance (VeröffentlichungsVO) to section 82 (9) Austrian Stock Exchange Act (BörseG) considered treasury shares within the mea - [at noodls] - 11.07.2016 - Publication of a transaction regarding Erste Group shares in compliance with section 7 Publication Ordinance (VeröffentlichungsVO) to section 82 (9) Austrian Stock Exchange Act (BörseG) considered ...
07/11/16 03:44 PMStock Performance Rundown on: Emergent BioSolutions, Inc. (NYSE:EBS) - Press Telegraph

Social

About Emergent Biosolutions

Emergent Biosolutions logoEmergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NYSE
  • Symbol: EBS
  • CUSIP: 29089Q10
Key Metrics:
  • Previous Close: $33.44
  • 50 Day Moving Average: $34.18
  • 200 Day Moving Average: $36.53
  • P/E Ratio: 17.87
  • P/E Growth: 1.01
  • Market Cap: $1.34B
  • Beta: 1.27
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
Emergent Biosolutions (NYSE:EBS) Chart for Tuesday, July, 26, 2016